GeneralBreaking NewsBreakingLatest News
Kerala's Free SMA Treatment Program Faces Scrutiny Over Drug Labeling
Sentiment: NeutralHigh Priority
What Happened?
Kerala's free treatment for spinal muscular atrophy (SMA) is under scrutiny after a hospital distributed a generic drug labeled for clinical trials. Concerns have been raised about regulatory approval and parental consent.
Key points
- Kerala has provided free SMA treatment since 2022, benefiting around 200 children.
- The state replaced the original drug Evrysdi with a cheaper generic version, Natsmart.
- Parents noticed the new drug was labeled 'For Clinical Trials Only', raising concerns.
- The Kerala government has been criticized for potentially using children as test subjects.
- Hospital authorities claim the generic drug is approved by the Central Drugs Standard Control Organisation (CDSCO).
- Parents demand evidence that the generic drug is bioequivalent to the original.
Key insights
- The incident may lead to increased scrutiny of drug approval processes in India.
- Parents' concerns could prompt regulatory bodies to enhance transparency in drug labeling.
- This situation highlights the need for robust bioequivalence studies for generic drugs.
Why it matters
The controversy raises important questions about the safety and efficacy of treatments for rare genetic disorders.
Tags
Entities
Kerala· StateSMA· DiseaseNatco Pharma· CompanyEvrysdi· ProductSree Avittom Thirunal Hospital· OrganizationPinarayi Vijayan· PersonCure SMA Foundation of India· Organization
Source
India Today
